- Allergic responses are driven by mast cells and basophils.
- Most allergy treatments focus on stopping the effects of histamine or on dampening the body's overall immune response by use of steroids.
- This approach is not totally effective.
- New approach aims at eliminating the immunoglobulin E (IgE) receptor on the surface of mast cells to stop allergic reaction.
A method to stop allergic reactions by removing a key receptor from mast cells and basophils, has been developed by researchers from North Carolina State University and the National Institutes of Health (NIH).
Their work has implications for the treatment of skin allergies and asthma.
Asthma and allergic diseases affect up to 20% of people in developed countries, and their prevalence is increasing.
When body comes into contact with an allergen, immunoglobulin E (IgE) specific to that allergen acts through its receptor on the mast cell, stimulating the mast cells and basophils to release mediators, such as histamine, that trigger an allergic response.
Currently, most allergy treatments focus on either stopping the effects of histamine and other mediators or on dampening the body's overall immune response by use of steroids.
Unfortunately neither approach is totally effective, and in the case of dampening the immune response, can have significant drawbacks.
Glenn Cruse, formerly of the NIH, current assistant professor of immunology at NC State and corresponding author of a paper describing the work, along with NIH colleague and co-author Dean Metcalfe, wanted to try and block the allergic reaction at its source.
Cruse and Metcalfe looked at a gene called MS4A2, which is only expressed in mast cells and basophils, and is responsible for forming the IgE receptor on the mast cell.
The researchers utilized a technique known as exon skipping, a form of RNA splicing, to eliminate the portion of one of the IgE receptor gene's mRNA that is essential to making a protein which places the IgE receptor on the mast cell surface.
The cell's DNA remains unaffected.
When the exon targeting therapy is stopped, the protein blocked by exon skipping is made again.
Cruse and Metcalfe tested their therapy on mast cells in vitro - where it eliminated activation of mast cells by allergen - and against allergic dermatitis in vivo, using a mouse model. Their results in vivo showed a marked reduction in the allergic dermatitis response in the mice.
"By eliminating the expression of the IgE receptor on the surface of mast cells, we have identified an innovative and targeted approach with the potential to treat allergic inflammation in millions of patients worldwide."says Cruse.
Due to the specificity of approach for mast cells and basophils, it should have significant advantages over current therapies.
Though the findings are very promising, researchers are still in the early stages of developing this therapeutic approach.
The research appears in Proceedings of the National Academy of Sciences. Funding was provided by the NIH Division of Intramural Research of NIAID and NHLBI.